非心脏手术后新发房颤与血栓栓塞长期风险
基于丹麦全国登记数据,1996至2015年非心脏手术后新发术后房颤(POAF)患者6048例(0.4%),按1:4匹配非手术非瓣膜性房颤(NVAF)患者。POAF与NVAF长期血栓栓塞风险相似(31.7 vs 29.9事件/1000人年;HR 0.95,95%CI 0.85-1.07),抗凝治疗在两组均与血栓栓塞风险降低相关。
要点
- 非心脏手术后新发POAF患者长期血栓栓塞风险与NVAF患者相似。
- POAF患者出院30天内启动口服抗凝比例低于NVAF患者(24.3% vs 41.3%)。
- 随访期抗凝治疗与POAF及NVAF患者血栓栓塞风险降低均相关。
核心结论
- 非心脏手术后新发POAF与NVAF患者长期血栓栓塞风险相似。
研究设计与样本
- 基于丹麦全国登记数据的匹配队列研究,纳入1996至2015年非心脏手术后新发POAF患者,按年龄、性别、心衰、高血压、糖尿病、既往血栓栓塞、缺血性心脏病和诊断年份以1:4匹配非手术NVAF患者。
- 共6048例(0.4%)非心脏手术住院期间发生POAF,3830例POAF患者匹配15320例NVAF患者。
主要发现
- POAF在胸部/肺部、血管和腹部手术后发生率最高。
- 出院30天内启动口服抗凝治疗的比例在POAF组为24.3%,NVAF组为41.3%(p<0.001)。
- 长期血栓栓塞风险在POAF与NVAF组相似(31.7 vs 29.9事件/1000人年;HR 0.95;95%CI 0.85-1.07)。
- 随访期抗凝治疗与血栓栓塞风险降低相关:POAF组HR 0.52(95%CI 0.40-0.67),NVAF组HR 0.56(95%CI 0.51-0.62)。
临床怎么用
- 非心脏手术后新发POAF患者应被视为长期血栓栓塞高风险人群,可参考NVAF风险评估与管理策略。
- 需关注POAF患者出院后抗凝治疗启动率偏低的现象,个体化评估抗凝获益与风险。
局限性
- 观察性登记研究,抗凝治疗非随机分配,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term risk of thromboembolism in patients developing new-onset post-operative atrial fibrillation (POAF) following noncardiac surgery is unknown, and data on stroke prophylaxis in this setting are lacking. OBJECTIVES: The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). METHODS: Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes, previous thromboembolism, ischemic heart disease, and year of diagnosis to patients with nonsurgical NVAF in a 1:4 ratio. Comparative long-term risk of thromboembolism was examined by multivariable Cox regression models. RESULTS: In patients undergoing noncardiac surgery, 6,048 (0.4%) developed POAF during hospitalization, with the highest incidences following thoracic/pulmonary, vascular, and abdominal surgery. A total of 3,830 patients with POAF were matched with 15,320 patients with NVAF. Oral anticoagulation therapy was initiated within 30 days post-discharge in 24.3% and 41.3% of these patients, respectively (p value <0.001). The long-term risk of thromboembolism was similar in patients with POAF and NVAF (31.7 events vs. 29.9 events per 1,000 person years; hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.85 to 1.07). Anticoagulation therapy during follow-up was associated with a comparably lowered risk of thromboembolic events in patients with POAF (HR: 0.52; 95% CI: 0.40 to 0.67) as well as NVAF (HR: 0.56; 95% CI: 0.51 to 0.62) compared with no anticoagulation therapy. CONCLUSIONS: New-onset POAF following noncardiac surgery was associated with a long-term risk of thromboembolism similar to NVAF.
引用
- Butt JH, Olesen JB, Havers-Borgersen E, et al. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. J Am Coll Cardiol. 2018. PMID: 30336826. doi:10.1016/j.jacc.2018.07.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。